June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Posterior iris-claw aphakic intraocular lens implantation in children
Author Affiliations & Notes
  • Johannes Gonnermann
    Ophthalmology, University Medicine Charité, Berlin, Germany
  • Necip Torun
    Ophthalmology, University Medicine Charité, Berlin, Germany
  • Matthias Klamann
    Ophthalmology, University Medicine Charité, Berlin, Germany
  • Anna-Karina Maier
    Ophthalmology, University Medicine Charité, Berlin, Germany
  • Peter Rieck
    Ophthalmology, University Medicine Charité, Berlin, Germany
  • Eckart Bertelmann
    Ophthalmology, University Medicine Charité, Berlin, Germany
  • Footnotes
    Commercial Relationships Johannes Gonnermann, None; Necip Torun, None; Matthias Klamann, None; Anna-Karina Maier, None; Peter Rieck, None; Eckart Bertelmann, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1845. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Johannes Gonnermann, Necip Torun, Matthias Klamann, Anna-Karina Maier, Peter Rieck, Eckart Bertelmann; Posterior iris-claw aphakic intraocular lens implantation in children. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1845.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the indications, visual outcomes, and complication rate after posterior implantation of an iris-claw aphakic intraocular lens (IOL) in children.

Methods: Eyes without adequate capsule support had posterior chamber iris-claw aphakic IOL implantation (Verisyse/Artisan) between 2007 and 2012.

Results: This non-comparative retrospective cohort study comprised 7 eyes (4 children). The mean follow-up was 31 months (range 10 to 64 months). In all eyes, the mean postoperative best spectacle-corrected visual acuity (0.13 ± 0.17 logMAR) was statistically significantly better at the last follow-up than 1 day preoperatively (0.60 ± 0.39 logMAR) (P < .05). The mean endothelial cell loss decreased from 3013 ± 155 cells/mm2 preoperatively to 2831 ± 236 cells/mm2 at last follow-up, representing a mean endothelial cell loss of 6.4%. No secondary glaucoma or pupillary block occurred after surgery in any eye.

Conclusions: The posterior implantation technique of Verisyse/Artisan aphakic iris-claw IOL provided good visual outcomes with a favorable complication rate and can be used as a reasonable alternative for a wide range of indications in pediatric eyes without adequate capsule support.

Keywords: 445 cataract  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×